Clinical Trial Update: A Phase 3 Extension Study of RAD011 (Cannabidiol Oral Solution) in Patients With Prader-Willi Syndrome [Phase 3]

View source ↗

Summary

Phase 3 extension study of RAD011 (cannabidiol oral solution) for Prader-Willi Syndrome has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prader-willi Syndrome

Drugs mentioned

• RAD011 (cannabidiol)

Snippet

Sponsor: Radius Pharmaceuticals, Inc. | Conditions: Prader-Willi Syndrome | Phase 3 | Status: WITHDRAWN